GlassScriptPhysician profile
Martin Defrancesco
NPI 1770501835
$627.88
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2023: $72.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $265.49 | 2019 | |
| Minerva Surgical, INC | $144.36 | 2019 | |
| Astellas Pharma US INC | $72.99 | 2023 | |
| Pfizer INC. | $35.76 | 2019 | |
| Amag Pharmaceuticals, INC. | $24.27 | 2019 | |
| Roche Diagnostics Corporation | $21.72 | 2019 | |
| Exeltis, USA INC. | $19.71 | 2019 | |
| Mission Pharmacal Company | $15.73 | 2019 | |
| Therapeuticsmd, INC. | $15.57 | 2019 | |
| Lupin INC. | $12.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Defrancesco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.